Novelix Pharmaceuticals (BOM:536565) Cyclically Adjusted Revenue per Share: ₹23.45 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:536565 Novelix Pharmaceuticals Ltd BOM:536565
50 GF Score
Price ₹82.50
! 7 Warning Signs
View Full Analysis

What is Novelix Pharmaceuticals Cyclically Adjusted Revenue per Share?

Novelix Pharmaceuticals BOM:536565 +0.73% 50 Cyclically Adjusted Revenue per Share is ₹23.45 as of Jun. 2026. GuruFocus rates BOM:536565 with a GF Score™ of 50/100. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novelix Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹15.343. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹23.45 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Novelix Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 50.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novelix Pharmaceuticals was 22.20% per year. The lowest was -0.10% per year. And the median was 11.05% per year.

As of today (2026-09-01), Novelix Pharmaceuticals's current stock price is ₹82.50. Novelix Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹23.45. Novelix Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 3.52.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novelix Pharmaceuticals was 3.79. The lowest was 0.39. And the median was 0.96.


Novelix Pharmaceuticals  (BOM:536565) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novelix Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=82.50/23.45
=3.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novelix Pharmaceuticals was 3.79. The lowest was 0.39. And the median was 0.96.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novelix Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Novelix Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Novelix Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelix Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Novelix Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.89 11.96 11.59 13.84 21.80

Novelix Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.58 18.09 20.79 21.80 23.45

BOM:536565 vs MCK, COR, CAH: Cyclically Adjusted Revenue per Share Comparison

For the Medical Distribution subindustry, Novelix Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novelix Pharmaceuticals Cyclically Adjusted PS Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Novelix Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novelix Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:536565
50GF Score
Novelix Pharmaceuticals Ltd BOM:536565
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novelix Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novelix Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.343/167.3573*167.3573
=15.343

Current CPI (Jun. 2026) = 167.3573.

Novelix Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 1.849 102.901 3.007
201603 1.597 102.518 2.607
201606 3.633 105.961 5.738
201609 2.497 105.961 3.944
201612 2.563 105.196 4.078
201703 2.443 105.196 3.887
201803 4.292 109.786 6.543
201806 4.733 111.317 7.116
201809 2.529 115.142 3.676
201812 3.174 115.142 4.613
201903 2.444 118.202 3.460
201906 3.008 120.880 4.165
201909 3.204 123.175 4.353
201912 3.114 126.235 4.128
202003 3.287 124.705 4.411
202006 2.537 127.000 3.343
202009 3.428 130.118 4.409
202012 2.467 130.889 3.154
202103 3.340 131.771 4.242
202106 5.367 134.084 6.699
202109 2.753 135.847 3.392
202112 0.146 138.161 0.177
202203 0.105 138.822 0.127
202206 0.075 142.347 0.088
202209 0.056 144.661 0.065
202212 0.592 145.763 0.680
202303 1.101 146.865 1.255
202306 2.432 150.280 2.708
202309 1.146 151.492 1.266
202312 0.672 152.924 0.735
202403 1.041 153.035 1.138
202406 0.730 155.789 0.784
202409 4.888 157.882 5.181
202412 5.375 158.323 5.682
202503 20.575 157.552 21.856
202506 18.800 159.755 19.695
202509 25.235 162.289 26.023
202512 27.951 163.281 28.649
202603 11.880 164.272 12.103
202606 15.343 167.357 15.343

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹23.45 mean?
Novelix Pharmaceuticals (BOM:536565) has a Cyclically Adjusted Revenue per Share of ₹23.45 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novelix Pharmaceuticals and its competitors.
Is Novelix Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Novelix Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹23.45. Overall, Novelix Pharmaceuticals has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to MCK and COR?
Novelix Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹23.45 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Distribution company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Distribution industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novelix Pharmaceuticals and its competitors. Novelix Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹23.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Novelix Pharmaceuticals (BOM:536565) has a current Cyclically Adjusted Revenue per Share of ₹23.45. The current Cyclically Adjusted Revenue per Share is ₹23.45. Novelix Pharmaceuticals' overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current Cyclically Adjusted Revenue per Share is ₹23.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novelix Pharmaceuticals Business Description

Address Lingapur LA Builders, Amrutha Estates, 6th floor, House no. 3-6-237/610, Himayath nagar, Hyderabad, TG, IND, 500029
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
50GF Score

Get the complete analysis for BOM:536565

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹82.50
Price